Column

Pharma Insights

The Challenge With Today’s Value Assessments: Not Evolving With the Evidence

04/16/2019

The methodologies employed within value assessments, especially by the Institute for Clinical and Economic Review (ICER), primarily measure value through quality-adjusted life-years (QALYs). While also the common...

The...

04/16/2019

Journal of Clinical Pathways

Business of Pathways

Why Threshold Target Performance-Based Metrics May Not Improve Population Health as Much as Treatment Pathways

04/16/2019

Ira Klein , MD, MBA, FACP;

Cheryl Neslusan , PhD;

Pierre Johansen , MSc;

Christian Asseburg , PhD;

Duncan O'Brien , BEc;

Michael Willis , PhD;

Silas Martin , MS;

Many value-based payment agreements (VBAs) and programs incentivize physicians to provide care based on patients’ achievement of treatment targets, especially threshold-based metrics such as maintaining a...

Many...

04/16/2019

Journal of Clinical Pathways

Editor's Page

Optimizing Resource Utilization and the Need for Enhanced Value Frameworks

03/14/2019

Winston Wong , PharmD;

Continued innovations in oncology hold the promise of survival improvements. However, new treatments introduce significant challenges for patients, such as higher out-of-pocket expenses and new toxicities. Likewise,...

...

03/14/2019

Journal of Clinical Pathways

PATIENT PERSPECTIVE

How Pathways Can Support Reimbursement for Personalized Decision Making and Care Planning

03/13/2019

Alan J. Balch , PhD, MSc;

The ideal way to manage the utilization of health care resources in an era of value-based and precision medicine is to require and provide reimbursement for personalized decision making and care planning with...

The...

03/13/2019

Journal of Clinical Pathways

Business of Pathways

Eliminating Low-Value Health Care: Where Pathways Approaches Have Succeeded

03/13/2019

Ira Klein , MD, MBA, FACP;

Low-value health care continues to put stress on the US economy, as 20% to 40% of all health spending is designated as wasteful. To date, there have been few broad and sustained efforts to reign in wasteful spending....

...

03/13/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Centers of Excellence: Criteria and Comprehensive Clinical Pathways

03/13/2019

Matthew Pakizegee , PharmD, MS;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Center of Excellence (CoE) model of care is an excellent approach to the growing need for disease-based medical management of chronic-type conditions with its multidisciplinary team approach and dedication to...

The...

03/13/2019

Journal of Clinical Pathways

Pharma Insights

Value Transformation: Observations on the Second Annual Evaluation Report of the Oncology Care Model

03/13/2019

Maureen Hennessey , PhD, CPCC, CPHQ;

Larry Blandford , PharmD;

Linda Bolland , PharmD, MBA;

The Centers for Medicare & Medicaid Services (CMS) posted its second annual evaluation report of the Oncology Care Model (OCM) in December 2018, covering first performance period and model year results. This...

The...

03/13/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Pathways for Paying for Rare Disease Treatments

02/22/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access. Novel and expensive therapies will create financial pressure for...

...

02/22/2019

Journal of Clinical Pathways

Editor's Page

Quantifying Resource Use and the Role of Pathways in Reimbursement

02/19/2019

Winston Wong , PharmD;

The delivery of cancer care is inevitably influenced by payment forces. In the ongoing transition from volume- to value-based payment, clinical pathways can serve as an integral tool for successful and streamlined...

The...

02/19/2019

Journal of Clinical Pathways

Editorial

#COA2019: The Most Comprehensive Meeting for Community Oncology

02/19/2019

Nicolas Ferreyros ;

The 2019 Community Oncology Conference will focus on ensuring quality, affordable, and accessible cancer care. This will include 2 days full of learning and networking with community oncology practices and allied...

The...

02/19/2019

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products